Идёт набор NCT07690917

A Study of a New PET Scanner in People With Cancer

— Наблюдательное Non Small Cell Lung Carcinoma NSCLC Head and Neck Cancer Prostate Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Biograph Vision Quadra scanner, PET/CT.
Кому может быть актуально: Состояния в реестре: Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer, Prostate Cancer. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Quality Improvement Study of a New Generation of Whole Body PET Scanners

Обзор

The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.

Подробное описание

This protocol is a quality improvement protocol intended to explore and capitalize on the advanced performance characteristics of a new total body PET scanner; the Biograph Vision Quadra manufactured by Siemens Healthineers.

Вмешательства

Диагностический тест Biograph Vision Quadra scanner
new total-body PET scanner, 1 or 2 additional scans with the Biograph Vision Quadra scanner.
Диагностический тест PET/CT
Scheduled PET/CT scan

Первичные конечные точки

image quality [Срок оценки: 3 years]

Критерии участия

Критерии включения

Eligibility Criteria for objective #1:

Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
Patients who are undergoing a planned PET-CT scan at main campus of MSK.
Patients must be ≥ 18 years old

Eligibility Criteria for objective #2:

Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
Patients with metastatic prostate or head and neck cancer.
Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
Patients must be ≥ 18 years old

Eligibility Criteria for objective #3:

Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK.
Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
Patients must be ≥ 18 years old